Back
Speaker illustration

Doctor Laura Michael

Eli Lilly & Co, Indianapolis (United States of America)

Presentations

Discovery and preclinical development of LY3473329, a potent small molecule inhibitor of lipoprotein(a) formation

Event: ESC Congress 2023

Topic: Lipid-Lowering Agents

Session: Hypertriglyceridemia treatment: CEPT, icosapent ethyl, and fibrates

Access
Like
Thumbnail

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources